Rapamycin blocks production of KSHV/HHV8: Insights into the anti-tumor activity of an immunosuppressant drug

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Nichols, Lisa A ^a,b   Adang, Laura A ^a,b   Kedes, Dean H ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; REPLICATION AND TRANSACTIVATOR PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SWITCHING; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; PROTEIN DEPLETION; PROTEIN EXPRESSION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; KAPOSI SARCOMA; PHYSIOLOGY; VIROLOGY;

HUMAN HERPESVIRUS 8;

ANTIBIOTICS, ANTINEOPLASTIC; B-LYMPHOCYTES; CELL LINE; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SARCOMA, KAPOSI; SIROLIMUS; TOR SERINE-THREONINE KINASES; VIRUS REPLICATION;

EID: 79251584652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014535     Document Type: Article

References (68)

1. Moore PS, Chang Y (2001) Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philosophical Transactions of the Royal Society of London Series BBiological Sciences 356: 499-516.
2. Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, et al. (1996) Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. Journal of Virology 70: 549-558.
3. Grundhoff A, Ganem D (2004) Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113: 124-136.
4. Casper C, Nichols WG, Huang ML, Corey L, Wald A (2004) Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103: 1632-1634.
5. Lukac DM, Kirshner JR, Ganem D (1999) Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol 73: 9348-9361.
6. Xu YY, AuCoin DP, Huete AR, Cei SA, Hanson LJ, et al. (2005) A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. Journal of Virology 79: 3479-3487.
7. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu FX, et al. (1998) A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proceedings of the National Academy of Sciences of the United States of America 95: 10866-10871.
8. Shaw RN, Arbiser JL, Offermann MK (2000) Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. Aids 14: 899-902.
9. Yu YM, Black JB, Goldsmith CS, Browning PJ, Bhalla K, et al. (1999) Induction of human herpesvirus-8 DNA replication and transcription by butyrate and TPA in BCBL-1 cells. Journal of General Virology 80: 83-90.
10. Cai Q, Lan K, Verma SC, Si H, Lin D, et al. (2006) Kaposi's sarcomaassociated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. J Virol 80: 7965-7975.
11. Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL, et al. (2001) Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 97: 3244-3250.
12. Yilmaz R, Akoglu H, Kirkpantur A, Kilickap S, Arici M, et al. (2007) A Novel Immunosuppressive Agent, Sirolimus, in the Treatment of Kaposi's Sarcoma in a Renal Transplant Recipient. Ren Fail 29: 103-105.
13. Kolhe N, Mamode N, Van der Walt J, Pattison J (2006) Regression of posttransplant Kaposi's sarcoma using sirolimus. Int J Clin Pract 60: 1509-1512.
14. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, et al. (2007) Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 109: 2165-2173.
15. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, et al. (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317-1323.
16. Merimsky O, Jiveliouk I, Sagi-Eisenberg R (2008) Targeting mTOR in HIVNegative Classic Kaposi's Sarcoma. Sarcoma 2008: 825093.
17. Charfi S, Krichen-Makni S, Yaich S, Makni H, Khabir A, et al. (2007) Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment. Saudi J Kidney Dis Transpl 18: 617-620.
18. Garcia VD, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, et al. (2003) Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 16: 202-206.
19. Gutierrez-Dalmau A, Sanchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A, Franco A, et al. (2005) Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 37: 3836-3838.
20. Averous J, Proud CG (2006) When translation meets transformation: the Mtor story. Oncogene 25: 6423-6435.
21. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, et al. (2006) The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 10: 133-143.
22. Barozzi P, Riva G, Vallerini D, Bosco R, Quadrelli C, et al. (2009) Indirect antitumor effects of mammalian target of rapamycin inhibitors against Kaposi sarcoma in transplant patients. Transplantation 88: 597-598.
23. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, et al. (1996) Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 2: 342-346.
24. Tomescu C, Law WK, Kedes DH (2003) Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. J Virol 77: 9669-9684.
25. Lacombe F, Belloc F, Bernard P, Boisseau MR (1988) Evaluation of four methods of DNA distribution data analysis based on bromodeoxyuridine/DNA bivariate data. Cytometry 9: 245-253.
26. Kremer BE, Haystead T, Macara IG (2005) Mammalian septins regulate microtubule stability through interaction with the microtubule-binding protein MAP4. Mol Biol Cell 16: 4648-4659.
27. Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, et al. (1999) Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 73: 2232-2242.
28. Zhu FX, Cusano T, Yuan Y (1999) Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus. J Virol 73: 5556-5567.
29. Chung J, Kuo CJ, Crabtree GR, Blenis J (1992) Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69: 1227-1236.
30. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, et al. (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358: 70-73.
31. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257: 973-977.
32. Grandadam M, Dupin N, Calvez V, Gorin I, Blum L, et al. (1997) Exacerbations of clinical symptoms in human immunodeficiency virus type 1- infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 175: 1198-1201.
33. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, et al. (2000) High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 96: 2069-2073.
34. Whitby D, Howard MR, Tenantflowers M, Brink NS, Copas A, et al. (1995) Detection of Kaposi-Sarcoma Associated Herpesvirus in Peripheral-Blood of Hiv-Infected Individuals and Progression to Kaposis-Sarcoma. Lancet 346: 799-802.
35. Gonzalez-Lopez MA, Rodrigo E, Gonzalez-Vela MC, Fernandez-Llaca H, Arias-Rodriguez MA, et al. (2006) Posttransplant Kaposi's sarcoma restricted tothe site of a previous deep venous thrombosis: abrupt onset after withdrawal of sirolimus. Dermatology 213: 30-33.
36. Wasywich CA, Croxson MC, van Doornum GJ, Coverdale HA, Ruygrok PN (2006) Sirolimus for Kaposi's sarcoma. J Heart Lung Transplant 25: 726-729.
37. Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J (1995) Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 17: 666-671.
38. Adang LA, Parsons CH, Kedes DH (2006) Asynchronous progression through the lytic cascade and variations in intracellular viral loads revealed by highthroughput single-cell analysis of Kaposi's sarcoma-associated herpesvirus infection. J Virol 80: 10073-10082.
39. Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603.
40. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, et al. (2003) Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101: 278-285.
41. Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, et al. (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134: 475-484.
42. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM (2007) Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 83: 1114-1121.
43. Buchkovich NJ, Yu Y, Zampieri CA, Alwine JC (2008) The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signaling pathway. Nat Rev Microbiol 6: 266-275.
44. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, et al. (2004) Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirusencoded G protein-coupled receptor. Proc Natl Acad Sci U S A 101: 4821-4826.
45. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B (2006) Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 66: 3658-3666.
46. Lambert SL, Martinez OM (2007) Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 179: 8225-8234.
47. Moody CA, Scott RS, Amirghahari N, Nathan CO, Young LS, et al. (2005) Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 79: 5499-5506.
48. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
49. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, et al. (2003) Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 63: 4472-4480.
50. Montaner S, Sodhi A, Ramsdell AK, Martin D, Hu J, et al. (2006) The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res 66: 168-174.
51. Watanabe T, Sugaya M, Atkins AM, Aquilino EA, Yang A, et al. (2003) Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol 77: 6188-6196.
52. Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, et al. (2003) A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcomaassociated herpesvirus latency. Nat Med 9: 300-306.
53. Bubman D, Guasparri I, Cesarman E (2007) Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene.
54. Friborg J, Jr., Kong W, Hottiger MO, Nabel GJ (1999) p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402: 889-894.
55. Davis MA, Sturzl MA, Blasig C, Schreier A, Guo HG, et al. (1997) Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 89: 1868-1874.
56. Grundhoff A, Ganem D (2001) Mechanisms governing expression of the v-FLIP gene of Kaposi's sarcoma-associated herpesvirus. J Virol 75: 1857-1863.
57. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, et al. (2000) The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogenactivated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 60: 4873-4880.
58. Jham BC, Montaner S (2010) The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor: Lessons on dysregulated angiogenesis from a viral oncogene. J Cell Biochem 110: 1-9.
59. Bottero V, Sharma-Walia N, Kerur N, Paul AG, Sadagopan S, et al. (2009) Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression. Virology 392: 34-51.
60. Moorman NJ, Shenk T (2010) Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 84: 5260-5269.
61. Rose NJ, Lever AM (2007) Rapamycin-induced inhibition of HTLV-I LTR activity is rescued by c-Myb. Retrovirology 4: 24.
62. Roy J, Paquette JS, Fortin JF, Tremblay MJ (2002) The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 46: 3447-3455.
63. Avni D, Biberman Y, Meyuhas O (1997) The 59 terminal oligopyrimidine tract confers translational control on TOP mRNAs in a cell type- and sequence context-dependent manner. Nucleic Acids Res 25: 995-1001.
64. Hornstein E, Git A, Braunstein I, Avni D, Meyuhas O (1999) The expression of poly(A)-binding protein gene is translationally regulated in a growth-dependent fashion through a 59-terminal oligopyrimidine tract motif. J Biol Chem 274: 1708-1714.
65. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, et al. (2003) Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol 77: 4205-4220.
66. Erbay E, Park IH, Nuzzi PD, Schoenherr CJ, Chen J (2003) IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 163: 931-936.
67. Rose N, Lever A (2001) The rapamycin sensitivity of human T-cell leukaemia virus type I-induced T-cell proliferation is mediated independently of the polypyrimidine motifs in the 5' long terminal repeat. J Gen Virol 82: 435-439.
68. Arias C, Walsh D, Harbell J, Wilson AC, Mohr I (2009) Activation of host translational control pathways by a viral developmental switch. PLoS Pathog 5: e1000334.